Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.

Three spine surgeons from across the U.S. discuss where they see the biggest opportunities in spinal biologics and disc generation.

Aziyo Biologics launched OsteGro, an allograft bone matrix designed to support new bone growth in procedures such as hip reconstruction, bone fracture repair and spinal fusion.

Indianapolis-based orthopedic surgeon Greg Merrell, MD, treated the first U.S. patient in Cartiva's GRIP 2 study, evaluating the safety and effectiveness of the Cartiva Synthetic Cartilage Implant to treat osteoarthritis of the thumb. 

The global stem cell therapy market is projected to grow at a compound annual growth rate of 36.52 percent between 2017 and 2021, according to an analysis by Wise Guy Reports.

KICVentures acquired Amend Surgical, a company developing synthetic bioactive glass products.

Orthobiologics company Cerapedics received FDA approval to initiate a study of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion surgery for degenerative disc disease.

Gregory Lutz, MD, and Kevin Pauza, MD, launched a new study to examine the clinical effectiveness of Discseel, a treatment to restore and regrow damaged discs in the spine.

Mesenchymal stromal cells have shown promise for regenerative medicine, according to the Journal of Orthopaedics. They may improve spinal fusion.

 that demineralized bone matrix activity induces bone when implanted ectopically into the muscle or under the skin due to bone morphogenetic proteins.

The use of biologics before and during pregnancy is not associated with an increased risk of preterm delivery or small-for-gestational-age births, a study in Annals of the Rheumatic Diseases finds.

MedImmune will create a standalone company for early-stage inflammatory and autoimmunity biologics.

Surgeons attending the American Academy of Orthopaedic Surgeons 2018 Annual Meeting in New Orleans March 6 to 10 can expect to discuss biologics and opioids, according to Medscape.

Researchers grafted human spinal cord-derived neural progenitor cells into cervical spinal cord injury sites in rhesus monkeys in a study in Nature Medicine. The human stem cells matured into nerve cells in the monkeys, spurring neuronal connections and improving the monkeys' grip.

Researchers at the New York Genome Center and New York University in New York City developed a 3-D printed, portable and low-cost microfluidic device to facilitate access to single-cell sequencing. The researchers used the device to study synovial tissue from patients with rheumatoid arthritis at the New York City-based Hospital for Special Surgery and published their findings in Nature Communications.

Bioventus will co-develop a next generation bone allograft solution for spine and trauma surgery with Tampa, Fla.-based LifeLink Tissue Bank.

Johnson & Johnson is collaborating with Advanced Materials and BioEngineering Research to establish a 3-D bioprinting laboratory. Work on the new laboratory will begin in the first quarter of 2018.

The first patient in Centrexion Therapeutics Corp.'s Phase 3 VICTORY-1 clinical trial has been dosed with CNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.